Skip to main content

Table 3 Associations of CRH score with mortality in patients with various VHD

From: Assessment of cardio-renal-hepatic function in patients with valvular heart disease: a multi-biomarker approach—the cardio-renal-hepatic score

 

Univariable analysis

Multivariable analysisa

Unadjusted HR (95%CI)

P value

Adjusted HR (95%CI)

P value

Total Cohort ( n  = 6004)

 CRH score (per 1 point increase)

2.719 (2.503–2.954)

 < 0.001

2.095 (1.891–2.320)

 < 0.001

 CRH score

  Q2 vs Q1

3.636 (2.241–5.898)

 < 0.001

2.586 (1.583–4.223)

 < 0.001

  Q3 vs Q1

6.293 (3.965–9.989)

 < 0.001

3.652 (2.267–5.882)

 < 0.001

  Q4 vs Q1

21.246 (13.687–32.979)

 < 0.001

8.319 (5.182–13.355)

 < 0.001

AS ( n  = 328)

 CRH score (per 1 point increase)

2.086 (1.448–3.004)

 < 0.001

1.791 (1.018–3.148)

0.043

 CRH score

  Q2 vs Q1

1.478 (0.247–8.848)

0.669

1.036 (0.157–6.813)

0.971

  Q3 vs Q1

4.652 (1.005–21.538)

0.049

2.407 (0.473–12.240)

0.290

  Q4 vs Q1

7.873 (1.792–34.584)

0.006

2.990 (0.546–16.380)

0.207

AR ( n  = 780)

 CRH score (per 1 point increase)

3.416 (2.618–4.457)

 < 0.001

3.290 (2.245–4.821)

 < 0.001

 CRH score

  Q2 vs Q1

—

—

—

—

  Q3 vs Q1

—

—

—

—

  Q4 vs Q1

—

—

—

—

MS ( n  = 320) b

 CRH score (per 1 point increase)

7.279 (3.457–15.320)

 < 0.001

4.986 (2.069–12.016)

 < 0.001

 CRH score

  Q2 vs Q1

—

—

—

—

  Q3 vs Q1

—

—

—

—

  Q4 vs Q1

—

—

—

—

MR ( n  = 1677)

 CRH score (per 1 point increase)

2.552 (2.161–3.014)

 < 0.001

1.938 (1.573–2.389)

 < 0.001

 CRH score

  Q2 vs Q1

2.964 (1.260–6.973)

0.013

1.696 (0.708–4.064)

0.236

  Q3 vs Q1

5.416 (2.414–12.148)

 < 0.001

2.599 (1.118–6.044)

0.026

  Q4 vs Q1

13.451 (6.216–29.106)

 < 0.001

4.017 (1.720–9.381)

0.001

TR ( n  = 1085)

 CRH score (per 1 point increase)

2.676 (2.246–3.188)

 < 0.001

2.253 (1.808–2.808)

 < 0.001

 CRH score

  Q2 vs Q1

2.400 (0.922–6.247)

0.073

2.167 (0.816–5.752)

0.121

  Q3 vs Q1

3.973 (1.611–9.798)

0.003

3.361 (1.318–8.571)

0.011

  Q4 vs Q1

16.708 (7.293–38.279)

 < 0.001

10.502 (4.315–25.557)

 < 0.001

MVHD ( n  = 1814)

 CRH score (per 1 point increase)

2.611 (2.255–3.024)

 < 0.001

1.914 (1.603–2.284)

 < 0.001

 CRH score

  Q2 vs Q1

1.977 (1.104–3.539)

0.022

1.474 (0.817–2.657)

0.198

  Q3 vs Q1

3.752 (2.190–6.429)

 < 0.001

2.076 (1.182–3.647)

0.011

  Q4 vs Q1

9.788 (5.904–16.228)

 < 0.001

3.931 (2.258–6.844)

 < 0.001

  1. CRH cardio-renal-hepatic, VHD valvular heart disease, AS aortic stenosis, AR aortic regurgitation, MS mitral stenosis, MR mitral regurgitation, TR tricuspid regurgitation, MVHD multiple valvular heart disease, BMI body mass index, NYHA New York Heart Association, LA left atrial end-diastolic dimension, LVEDD left ventricular end-diastolic dimension, LVEF left ventricular ejection fraction, HR hazard ratio, CI confidence interval
  2. aAdjusted for age, sex, BMI, smoking status, hypertension, hyperlipidemia, diabetes, prior myocardial infarction, cardiomyopathy, atrial fibrillation or flutter, chronic lung disease, NYHA functional class, hemoglobin, LA, LVEDD, LVEF, pulmonary hypertension, severity of VHD, and valvular intervention
  3. bAdjusted for age and sex
Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us